E. Efstathiou reports on study results presented on prostate cancer at ASCO 2019. She explains the benefits of adding hormonal agents early in the disease spectrum, and discusses the prospect of combinatorial strategies based on biomarkers selection.

- LBA2 / Overall survival (OS) results of ENZAMET (ANZUP 1304) trial
- Abstract 5006 / First results from TITAN trial
- Abstract 5008 / Alliance A031201: A phase III trial in mCRPC

Major Sponsors

AstraZeneca Bristol-Myers Squibb MSD Servier

Main Sponsors

Astellas Bayer Healthcare Boehringer Ingelheim Daiichi Sankyo ipsen Janssen logo Novartis Roche